2024 Stock Picks

metalztrader said:
Not sure about the other ones but thanks for AJG. I am going to buy some tomorrow for a purely technical swing trade. I don't even remember what the actual business name is or what they do but I like how it looks in my charting software. Trading something with no opinion on the business will be really interesting. It might be something I have to explore more with just a basket of tickers and a scanner.
More...


AJG uptrend started a decade ago.
It is still on the uptrend.

It has since appreciated 7X already.
 
vanzandt said:
I'm gonna add AMZN too, even though a mag-7 stock kinda takes the fun out of it... but ya gotta call a spade a spade.

Cramer paraphrased me again tonight regarding this one... and no, I don't think he reads ET lol.... but he did affirm what I wrote last week. "The sum of the parts".

https://www.elitetrader.com/et/threads/gba-presents-house-of-gummy.374311/page-1087#post-5904169

He liked that concept for several of the mag-7.... personally, I kind of agree.
More...



Needham say’s AMZN Top 2024 pick, did you tell their analyst?
 
2rosy said:
Monopolies on the dip. Opinions on china?
More...
The financial press/media seems slightly bearish on China, but fwiw, earlier this week I saw several cases of bullish option flows into a few of the etfs that track China. Today for example ASHR ----> the January $25 calls. And they have been buying those all week. Granted they are only $0.07, but someone seems to want a lot of those lottery tickets. Seems like a reach if you ask me, but who knows.

There were a couple more I've seen in the last few days... no stocks, just high volume etf order flow on the buy side. I don't really follow them, I only noticed them because they showed up on my screeners.
 
Maverick2608 said:
ALT

When I entered after the phase 2b data just days ago, it was trading close to net cash even though the data seems to be as good as Novo's Wegovy.

Big pharma are hungry for a weight loss GLP-1 drug of their own. Novo has become the largest company in Europe because of their GLP-1.

ALT will most likely secure a partner before phase 3.

Big upside. Limited downside before phase 3 data.

ALT current market cap: USD 429 million
NVO current market cap: USD 452 billion (yes there is more to NVO than Wegovy)

ALT current price: 7.98

December 1, 2023:
"Altimmune price target raised to $25 from $16 at JMP Securities
JMP Securities raised the firm's price target on Altimmune to $25 from $16 and keeps an Outperform rating on the shares.

Following the Phase 2b MOMENTUM data, the firm is now including obesity as a separate program in its Altimmune valuation. The shares are up 50% today but this still undervalues pemvidutide's opportunity that JMP now models at over $5B in peak sales between obesity and nonalcoholic steatohepatitis, the analyst tells investors in a research note. The firm continues to recommend Altimmune shares, saying pemvidutide has a competitive profile."
More...
Nice call! Check it out.
 
Two more stocks that I keep track of. Neither will move fast, but for a 12 month time-frame assuming no large market-wide correction, they'll slowly grind up.

AIR-- it sold off today on a revenue miss. $64.30 now. It's a solid company, in the right sector. Low volume. It's an off the radar type stock. It's the type of stock Berkshire would buy, and hold for 10 years.

BJ-- They're growing, like a Costco, membership club. $66. It's overdue to live north of $70 and start grinding towards $80.

AIR might pull back some more as this is day 1 on the sell off. Anything below $60 would be great.
 
You must log in or register to reply here.
Back
Top